Mechanisms and Clinical Manifestations of Cognitive Decline in Atrial Fibrillation Patients: Potential Implications for Preventing Dementia

被引:12
|
作者
Blum, Steffen [1 ,2 ]
Conen, David [2 ,3 ]
机构
[1] Univ Basel, Univ Hosp Basel, Cardiovasc Res Inst Basel, Basel, Switzerland
[2] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada
[3] Populat Hlth Res Inst, 237 Barton St East, Hamilton, ON L8L 2X2, Canada
关键词
SPONTANEOUS INTRACEREBRAL HEMORRHAGE; VASCULAR RISK-FACTORS; INCIDENT DEMENTIA; CEREBRAL MICROBLEEDS; CATHETER ABLATION; BLOOD-PRESSURE; ATHEROSCLEROSIS RISK; DIABETES-MELLITUS; ISCHEMIC-STROKE; ALZHEIMERS-DISEASE;
D O I
10.1016/j.cjca.2022.10.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atrial fibrillation (AF) patients face an approximate 1.5-fold increased risk of cognitive decline compared with the general population. Among poststroke AF patients, the risk of cognitive decline is even higher with an estimated threefold increase. This article provides a narrative re-view on the current evidence and highlights gaps in knowledge and areas for future research. Although earlier studies hypothesized that the association between AF and cognitive decline is mainly a conse-quence of previous ischemic strokes, more recent evidence also sug -gests such an association in AF patients without a history of clinical stroke. Because AF and cognitive decline mainly occur among elderly individuals, it is not surprising that both entities share multiple risk factors. In addition to clinically overt ischemic strokes, silent brain in-farcts and other brain injury are likely mechanisms for the increased risk of cognitive decline among AF patients. Oral anticoagulation for stroke prevention in AF patients with additional stroke risk factors is one of the only proven therapies to prevent brain injury. Whether a broader use of oral anticoagulation, or more intense anticoagulation in some patients are beneficial in this context needs to be addressed in future studies. Although direct studies are lacking, it is reasonable to recommend optimal treatment of comorbidities and risk factors for the prevention of cognitive decline and dementia.
引用
收藏
页码:159 / 171
页数:13
相关论文
共 50 条
  • [11] Impact of anticoagulation therapy on the cognitive decline and dementia in patients with non-valvular atrial fibrillation (cognitive decline and dementia in patients with non-valvular atrial fibrillation [CAF] trial)
    Bunch, Thomas Jared
    May, Heidi
    Cutler, Michael
    Woller, Scott C.
    Jacobs, Victoria
    Stevens, Scott M.
    Carlquist, John
    Knowlton, Kirk U.
    Muhlestein, Joseph B.
    Steinberg, Benjamin A.
    Anderson, Jeffrey L.
    JOURNAL OF ARRHYTHMIA, 2022, 38 (06) : 997 - 1008
  • [12] Atrial fibrillation as an important clinical condition of cognitive decline; diagnosis, comorbidities and severity of symptoms in patients with dementia
    Niedziela, Natalia
    Nowak, Maria Magdalena
    Lis, Martyna
    Blaszkowska, Maria
    Kosmider, Rozalia
    Adamczyk-Sowa, Monika
    NEUROLOGICAL RESEARCH, 2020, 42 (05) : 430 - 438
  • [13] Novel Therapeutic Target of Anticoagulation Therapy in Patients With Atrial Fibrillation -Cognitive Decline and Dementia -
    Kodani, Eitaro
    Nagao, Takehiko
    CIRCULATION JOURNAL, 2018, 82 (03) : 644 - 645
  • [14] Dementia and Atrial Fibrillation: Pathophysiological Mechanisms and Therapeutic Implications
    Chopard, Romain
    Piazza, Gregory
    Gale, Seth Alan
    Campia, Umberto
    Albertsen, Ida Ehlers
    Kim, Jisoo
    Goldhaber, Samuel Z.
    AMERICAN JOURNAL OF MEDICINE, 2018, 131 (12): : 1408 - 1417
  • [15] Cardiac Fibrosis in Patients With Atrial Fibrillation Mechanisms and Clinical Implications
    Dzeshka, Mikhail S.
    Lip, Gregory Y. H.
    Snezhitskiy, Viktor
    Shantsila, Eduard
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 66 (08) : 943 - 959
  • [16] Mechanisms, Clinical Significance, and Prevention of Cognitive Impairment in Patients With Atrial Fibrillation
    Rivard, Lena
    Khairy, Paul
    CANADIAN JOURNAL OF CARDIOLOGY, 2017, 33 (12) : 1556 - 1564
  • [17] Biomarkers for the prediction of cognitive decline in atrial fibrillation patients
    Krisai, P.
    Eberl, M.
    Coslovsky, M.
    Rodondi, N.
    Chocano-Bedoya, P.
    Kobza, R.
    Moschovitis, G.
    Rigamonti, E.
    Beer, J. H.
    Mueller, A.
    Reichlin, T.
    Conen, D.
    Osswald, S.
    Bonati, L.
    Kuehne, M.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [18] Brain lesions and cognitive decline in patients with atrial fibrillation
    Bhend, Katalin
    Paladini, Rebecca
    Aeschbacher, Stefanie
    Hennings, Elisa
    Coslovsky, Michael
    Rodondi, Nicolas
    Beer, Jurg
    Auricchio, Angelo
    Moschovitis, Giorgio
    Schorrer, Nino
    Chocano, Patricia
    Rigamonti, Elia
    Sinnecker, Tim
    Conen, David
    Kuhne, Michael
    Bonati, Leo
    Osswald, Stefan
    SWISS MEDICAL WEEKLY, 2023, 153 : 75S - 75S
  • [19] Gut microbiota, dysbiosis and atrial fibrillation. Arrhythmogenic mechanisms and potential clinical implications
    Gawalko, Monika
    Agbaedeng, Thomas A.
    Saljic, Arnela
    Mueller, Dominik N.
    Wilck, Nicola
    Schnabel, Renate
    Penders, John
    Rienstra, Michiel
    van Gelder, Isabelle
    Jespersen, Thomas
    Schotten, Ulrich
    Crijns, Harry J. G. M.
    Kalman, Jonathan M.
    Sanders, Prashanthan
    Nattel, Stanley
    Dobrev, Dobromir
    Linz, Dominik
    CARDIOVASCULAR RESEARCH, 2022, 118 (11) : 2415 - 2427
  • [20] Epicardial adipose tissue and atrial fibrillation: pathophysiological mechanisms, clinical implications, and potential therapies
    Goudis, Christos A.
    Vasileiadis, Ioannis E.
    Liu, Tong
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (11) : 1933 - 1943